Dual chamber prefilled syringes market is estimated to be valued at $ 184.7 Mn in 2025, and is expected to reach $ 306.6 Mn by 2032, exhibiting a CAGR of 7.5%. BURLINGAME, CA, UNI ...

The global market for prefilled syringes is expanding, driven by the rising prevalence of chronic illnesses, greater use of biologics and biosimilars, and a growing trend toward self-injection.

The company’s $3 billion in earnings for the first quarter missed on both top and bottom line, according to BMO Capital ...

The global market for prefilled syringes is expanding, driven by the rising prevalence of chronic illnesses, greater use of biologics and biosimilars, and a growing trend toward self-injection.

The U.S. Food and Drug Administration has approved a prefilled syringe version of Netherlands-based Argenx SE's blockbuster immune disorder drug, Vyvgart, giving patients a more convenient option of ...

The US Food and Drug Administration (FDA) has approved a pre-filled syringe version of argenx’s Vyvgart, giving generalised myasthenia gravis (gMG) and chronic inflammatory demyelinating ...

Vyvgart Hytrulo prefilled syringe for self-injection is approved as a 20-to-30-second subcutaneous injection administered by a patient, caregiver, or healthcare professional. The single-dose ...

After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull ...

The differences between PFSs and MDVs (per 1000 doses) is 324.21. MDV: Multidose vial; NA: Not available; PFS: Prefilled syringe. Prefilled syringes (PFSs) have gained market share in the USA ...

FDA approved Vyvgart Hytrulo prefilled syringe for gMG and CIDP self-injection in 20–30 seconds. Human factor studies showed patients and caregivers safely administered the new formulation.

Biocon Biologics' biosimilar Yesintek is approved for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis ...

Along with PCI's own robust infrastructure expansions, acquisition furthers CDMO's recent growth in sterile fill-finish, advanced drug delivery ...